In vitro enzymatic conversion of glycosylated human vitamin D binding protein to a potent macrophage activating factor
AssigneeNobuto Yamamoto
InventorNobuto Yamamoto
Life of this patent
Estimating the term…
Abstract
A novel, potent macrophage activating factor is prepared in vitro by treating glycosylated human group-specific component, also known as human vitamin D-binding protein, with glycosidases. Group-specific component, which is isolated from retired blood by known procedures, is thus readily converted to a highly potent macrophage activating factor.
Claims22
A process for producing a macrophage activating factor comprising contacting glycosylated human group-specific component in vitro with
- .beta.-galactosidase, or
- .beta.-galactosidase in combination with sialidase, .alpha.-mannosidase, or a mixture thereof,
- and obtaining the macrophage activating factor.
A macrophage activating composition comprising, in combination with a pharmaceutically acceptable carrier, a macrophage activating factor formed by treating glycosylated human group-specific component in vitro with
- .beta.-galactosidase or
- .beta.-galactosidase in combination with sialidase .alpha.-mannosidase, or mixtures thereof.
A method for inducing macrophage activation in an individual in need thereof comprising administering to such an individual macrophage activating factor prepared by contacting glycosylated human group-specific component in vitro with
- .beta.-galactosidase, or
- .beta.-galactosidase in combination with sialidase, .alpha.-mannosidase, or a mixture thereof.
Dependencies are inferred from the claim text.